Q2 2022 Kiniksa Pharmaceuticals Ltd Earnings Call
Okay.
Operator: Good morning and welcome to the Kiniksa Pharmaceuticals 2nd Quarter 2022 Financial Earnings Conference Call.
Good morning, and welcome to the connector Pharmaceuticals second quarter 2022 financial earnings Conference call.
Operator: All lines have been placed on mute to prevent any background noise.
All lines have been placed on mute to prevent any background noise.
Operator: After the speaker's remarks, there will be a question and answer session.
After the Speakers' remarks, there will be a question and answer session.
Operator: If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad.
If you would like to ask a question. During this time simply press star followed by the number one on your telephone keypad.
Operator: If you would like to withdraw your question, press the star 1 again.
If you would like to withdraw your question press the star one again.
Operator: For operator assistance throughout the call, please press star 0.
Operator assistance throughout the Cold place press Star Zero, and finally, I would like to advise all participants that this call is being recorded.
Operator: And finally, I would like to advise all participants that this call is being recorded.
Operator: Thank you.
I would now like to hand over to Rachel Frank head of IR.
Operator: I would now like to hand over to Rachel Frank, head of IR.
Thank you operator, good morning, everyone and thank you for joining this call to discuss our second quarter 2022 financial results and corporate update.
Rachel Frank: Thank you, operator.
Press release, highlighting these results can be found on our website under the investors and media section.
As for the agenda, our CEO songs keep hotel will start with an introduction Denny I bet you sorry, our Chief operating Officer, who will review our global license agreement with Genentech for the rights to develop and commercialize victrola math, which we get out this morning.
Ralph note, our Chief commercial officer, who will provide an update on our commercial execution and then Mark <unk>, Our Chief Financial Officer will review, our second quarter 2022 financial results.
And finally signs will return for closing remarks and to kick off the Q&A session for which John <unk>, Our Chief Medical Officer will also be on the line.
Before getting started please note that we will be making forward looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements are reviewed such statements and risk factors can be found on this slide as well as under the caption risk factors in our SEC filings.
These statements speak only as of the date of this presentation and we undertake no obligation to update such statements, except as required by law with that I will turn it over to <unk>.
Okay.
Rachel Frank: Good morning, everyone.
Thanks, Rachel and good morning, everyone I am really excited today to talk to you about two key updates first this morning, we announced a license agreement with Roche Genentech for the global rights to develop and commercialize fix it.
And then we'll cover the agreement in more detail, but under the terms of the deal <unk> expects to receive $100 million in upfront and near term payments.
We're proud to advanced VIX, whether or not from a preclinical stage program.
Phase two clinical studies, we believe our web underscores the differentiation potential of the mechanism as well as its potential to help patients with serious unmet need.
We plan to allocate the non diluted capital received from the transaction towards synergistic opportunities across our portfolio, including the expansion of <unk>.
<unk> cardiovascular franchise.
Rachel Frank: And thank you for joining Kiniksa's call to discuss our 2nd Quarter 2022 Financial Results and Corporate Update.
Additionally, on the commercial side I'm really happy to review our second quarter 2022 results. We reported today that net revenue for the second quarter of 2022 was $27 million.
Rachel Frank: Press release highlighting these results can be found on our website under the Investors and Media section.
Representing approximately 22% growth over the first quarter of 2022.
We are very pleased with the continued momentum of off list in recurrent pericarditis that we've seen to date.
<unk> will review our progress in more detail shortly.
The strong performance since launch warrant additional investment in the franchise and we are focused on expanding our portfolio by leveraging our cross functional cardiovascular expertise and infrastructure.
In addition, we remain focused on building the maximum value across our portfolio of clinical stage assets, which include Kpis for our C. D 40 program.
We're conducting a phase II clinical trial of KPN for in rheumatoid arthritis, which is designed to evaluate the efficacy.
Most response pharmacokinetics and the safety of chronic subcutaneous don't see over 12 weeks.
And finally for memory will remain highly encouraged by its broad potential which has been demonstrated by positive clinical data across multiple indications.
Sally waiting the next best steps for its development and rare cardiovascular diseases, where the GM CSF mechanism that's already been implicated.
So with that I'll turn it over to Evan to review, our global license agreement with Roche Genentech in more detail over to you and thanks guys.
As I just mentioned we are incredibly excited.
Sure enough disagreement clinical received $100 million in upfront and near term payments and are eligible to receive up to approximately $600 million in certain clinical regulatory and sales based milestones before fulfilling upstream obligations.
With our head licensee along with the milestones we are eligible to receive royalties on net sales Roche Genentech will obtain global rights in all fields for the development and commercialization of VIX for Allomap.
Can you say is completed screening patients for the <unk> clinical trial of <unk> in Prurigo <unk> and we plan to complete this trial the company will not disclose data in the second half of 2022 from this study.
Overall, we are incredibly proud to advanced Victor <unk> from our preclinical stage asset through phase II clinical studies, and we truly believe Roche Symantec as the right partner to maximize the future development potential <unk> with that I'll turn it over to Rob to review our commercial performance in more detail.
Rachel Frank: As for the agenda, our CEO, Sanj K. Patel, will start with an introduction.
Rachel Frank: Then Eben Tesari, our Chief Operating Officer, will review our global license agreement with Genentech for the right to develop and commercialize this gorilla map, which we announced this morning.
Thank you Evan Thank you I am pleased to share further information on our quarterly commercial performance and our plans for continued growth in recurrent pericarditis.
Rachel Frank: Ross Mote, our Chief Commercial Officer, will provide an update on our Arcalyst commercial execution.
Rachel Frank: And then Mark Rogosa, our Chief Financial Officer, will review our 2nd Quarter 2022 Financial Results.
Rachel Frank: And finally, Sanj will return for closing remarks and to kick off the Q&A session, for which John Paolini, our Chief Medical Officer, will also be on the line.
<unk> had some signs the Q2 represented another quarter of strong growth driven by patient identification and demand in recurrent pericarditis, which led to a quarterly growth of 22% or $4 8 million and resulted in a Q2 net revenue of $27 million in.
Rachel Frank: Before getting started, please note that we will be making forward-looking statements today that are subject to risks and uncertainties that may cause actual results to differ materially from these statements.
Rachel Frank: A review of such statements and risk factors can be found on this slide, as well as under the caption, Risk Factors, contained in our SEC filings.
Rachel Frank: These statements speak only as of the date of this presentation, and we undertake no obligation to update such statements, except as required by law.
Rachel Frank: With that, I will turn it over to Sanj.
Sanj Patel: Thanks, Rachel, and good morning, everyone.
In the first half of 2022, we recorded $49 $2 million net revenue and we continue to guide to a range of $115 million to $130 million for the totality of 2022.
Sanj Patel: I am really excited today to talk to you about two key updates. First, this morning, we announced a license agreement with Roche Genentech for the global rights to develop and commercialize the gorilla map. Evan will cover the agreement in more detail, but under the terms of the deal, Canixa expects to receive $100 million in up-front and near-term payments.
Sanj Patel: We're proud to advance VicSoilMap from a pre-clinical stage program through to phase two clinical studies. We believe our work underscores the differentiated potential of the mechanism, as well as its potential to help patients with serious unmet need.
Sanj Patel: We plan to allocate the non-diluted capital received from the transaction towards synergistic opportunities across our portfolio, including the expansion of our Arcalist cardiovascular franchise.
Sanj Patel: Additionally, on the commercial side, I'm really happy to review our second quarter 2022 results.
On slide 10, I will dive into more detail on the drivers behind the recurrent pericarditis revenue starting with physician growth as the awareness of <unk> list for recurrent pericarditis continues to grow so too does the number of physicians, who have prescribed <unk> since launch we've seen a growth of around 100 additional <unk>.
Sanj Patel: We reported today that net revenue for Arcalist for the second quarter of 2022 was $27 million, representing approximately 22% growth over the first quarter of 2022.
<unk> per quarter and in Q2, we saw this jumped to greater than 550 prescribers since launch.
We believe that by closely support and positions through that prescriber experience and patients throughout their journey on Atlas, we will trigger further prescribing when physicians identify the next appropriate patients.
Sanj Patel: Rydyn ni'n ddiolchgar iawn am y cynyddiad cyntaf o Arclist mewn pericarditis argyfwng, rydyn ni wedi'i weld ar ddiwedd, ac bydd Ross yn ymweld â'n cynyddiad yn fwy o ddetail yn ddiweddaraf.
Sanj Patel: Mae'r cynyddiadau'n fwyaf ers i'w lansio yn argyfwng addas i'r franchise, ac rydyn ni'n, seiliedig ar gynyddu ein portfolio trwy'n gweithredu ein gwybodaeth cardiovascular cross-functional a'r sefydliad.
We're starting to see that inflection of an ever increasing base. We now have 20% of the total prescriber base, who are prescribed for two or more patients.
This is excellent experience because prescribing biologics is still relatively new for many cardiologists. It's also crucial that they stay on the payer side that patients are getting access to therapy and on this note. We continue to see very high approval rates in the 90 plus percent Mark there.
Therefore, both prescribers and patients can be very confident that that prescription will result in access to therapy.
In terms of duration, while this will continue to evolve the data on hand continue to reflect continuous treatment durations of around 12 months of therapy. This insights is driven by most prescriptions being written for 12 months most payers a premium for 12 months prior to a reauthorization strong compliance and adherence to therapy and.
Around 45% of those earliest launch patients from Q2 2021 still being on continuous therapy through the end of Q2 2022.
Sanj Patel: Yn ogystal â hyn, rydyn ni'n ymweld â chynllunio'r waith mwyaf ar gyfer ein portfolio, o adnoddau cyfrifoldeb clinigol sy'n cynnwys y rhaglen KPL404, ein rhaglen CD40.
Sanj Patel: Yn ogystal â'r adnoddau clinigol, rydyn ni'n ymweld â'r adnoddau cyntaf ar gyfer ei ddatblygu, mewn rhaglenau cardiovascular rhaglenau, lle mae'r mecanismo GM-CSF wedi'i gysylltiedig.
Sanj Patel: Rydyn ni'n cymryd trial clinigol phas 2 o'r KPL404 ar gyfer arthritis rheumatoid, sy'n, cael ei dylunio i ddatblygu'r adnoddau, y cyfrifoldeb, y ffarmacol, a'r amgylchedd o adnoddau cyfrifoldeb cronig dros 12 wythnosau.
Lastly, our clusters received a very highest satisfaction rating from patients greater than 90% and we continue to hear directly and indirectly.
Sanj Patel: Felly, gyda hynny, byddaf yn mynd i Evan i ymweld â'n ymgysylltiad cymdeithasol globol gyda'r, Rheolwg Genedlaethol Cymru yn fwy o amgylchedd.
The transformational benefits Oculus is making to patients suffering from this debilitating flaring disease.
Moving to slide 11, I want to discuss why we're excited about the potential ahead as well as what we've learned since launch.
Sanj Patel: Iawn, Evan.
Eben Tessari: Diolch, Andrew.
First we've had a brilliant launch to date and we know the opportunity well there are 14000, multiple recurrent patients, meaning two or more of occurrences in any given year and given our broad label it could be utilized even earlier in the disease. After one recurrence. So we have a huge opportunity ahead.
Eben Tessari: Rydyn ni'n gyffredinol iawn i ymweld â'r ymgysylltiad hwnnw.
Eben Tessari: Bydd Cynigol yn cael $100 miliwn mewn penderfyniadau ar-lein a'r amgylchedd, ac mae'n, gyfathrebu i ddod o hyd i ymweld â chyfathrebu 600 miliwn mewn amgylcheddau clinigol, rheolaethol a'r amgylcheddau sy'n seiliedig, er mwyn cyfathrebu'r penderfyniadau ar-lein gyda'n ymgysylltiad cyntaf.
And we're in the very early days of the lifecycle.
Eben Tessari: Overall, we are incredibly proud to have advanced Vixorelumab from a preclinical stage, asset through phase two clinical studies, and we truly believe Roche Genentech is the right partner to maximize the future development potential of Vixorelumab.
Our field force is driving the adoption of our Atlas and helping to create a very positive patient and customer experience from research, we see that physicians become significantly more aware and knowledgeable of recurrent pericarditis and dark list and likelihood of intent to prescribe off list in the subsequent months significant.
<unk> increases with 88% of prescribers, who have met with a representative stating that that describe it will grow in the coming months.
Third there are only a small number of dedicated pericarditis centers, who have taken the lead on pericardial diseases.
This means that recurrent pericarditis patients are quite dispersed and the volume that each physician sees is relatively modest even within the same institution patients can presented on further occurrences to different physicians.
Therefore, given our success since launch and the positive impact our field team makes when Covid compositions, we plan to accelerate our coverage and reach by expanding our field team.
We strongly believe that this will allow us to increase market penetration and ultimately reach patients faster.
Turning to slide 12, I want to outline how we will evolve our field team.
As a reminder, we launched with a highly motivated and experienced field team of approximately 30 specialized cardiology representatives, who have been deliberate targeted and focused execution in the field. This lean team enabled us to cover around 45% of the recurrent pericarditis patients.
And we rapidly drove towards profitability for the franchise, which we achieved remarkably quickly in the third quarter of launch now.
Now we're actually in the learnings the allowance since our launch and aiming to accelerate our growth by evolving our sales team while maintaining profitability.
Since launch we have learned the importance of repeats colon on our target base as well as the need to switch our entire teams of cardiologists opposed to only individual doctors.
In Q4 this year, we plan to grow from around 30 Representatives to approximately 50, who will be able to cover 6000 health care professionals and around 70% of the recurrent pericarditis population.
Additionally, we have also added a small team of inside sales representatives as a cost effective approach to reach and some of the lower decile doctors there.
This exciting growth will not only create greater frequency with our high decile doctors, but will also accelerate our ability to reach a wider audience of cardiologists, who are managing recurrent pericarditis patients. The bottom line is we are really pleased with our initial ramps since launch we have a profitable franchise and we now invest in <unk>.
Further in the opportunity to transform the lives of recurrent pericarditis patients even quicker.
In summary, we believe we're at the beginnings of a robust trajectory a very sustainable profitable franchise since launch we've seen continuous steady sequential growth quarter on quarter physicians payers and patients continue to react extremely positive.
Creamy positively to artless availability and more and more patients against and appropriately diagnose and provided with a targeted treatment is designed to treat the underlying driver of the disease.
In the first half of 2022, we have recognized $49 2 million net revenue and we're guiding to $115 million to $130 million for the full year. We're very excited to take the steps to evolve our field team in Q4 and become even better faster stronger now.
Eben Tessari: With that, I'll turn it over to Ross to review our commercial performance in more detail.
I'll hand over to Mark to cover our financial results.
Ross Moat: Thank you, Evan.
Thanks, Ross Hello, everyone. Our detailed second quarter 2022 financial results can be found in the press release, we issued earlier today.
There are a few items I'd like to call your attention to this morning.
First as you have heard product revenue grew 22%.
Essentially in the second quarter to approximately $27 million, primarily due to <unk> sales and recurrent pericarditis.
Second collaboration expense in the second quarter was approximately $3 7 million based on an ARCUS collaboration profit of approximately seven 4 million.
Third total operating expenses and net loss were both lower year over year in the second quarter at approximately $46 3 million and $20 million, respectively. As arquebus sales ramped and programmatic spend decrease with the conclusion of the Rhapsody and Maverick trials.
Ross Moat: Thank you.
Fourth our net cash burn improved in the second quarter of this year with the receipt of the $22 million upfront payment from our collaboration with <unk> medicine.
Ross Moat: I'm pleased to share further information on our quarterly commercial performance and our, plans for continued growth in recurrent pericarditis. You've heard from Sanj that Q2 represented another quarter of strong growth driven by, patient identification and demand in recurrent pericarditis, which led to a quarterly growth of 22% or $4.8 million and resulted in a Q2 net revenue of $27 million.
And lastly, we remain well capitalized with a cash balance at the end of the second quarter of approximately $138 million and we expect these reserves combined with the proceeds from the fixed a global license agreement announced this morning as well as continued arcalis commercial execution to fund our current operating plan into at least 2025.
And with that I'll turn the call back to <unk> closing remarks.
Thanks, Mark in addition to our successful commercial launch and recurrent pericarditis with <unk>.
Also building a foundation is an emerging leader in immune modulating therapies.
We're focused on continuing to execute across our current portfolio as well as developing the portfolio in line with our existing cardiovascular expertise and infrastructure.
On the commercial side as Ralph said, where revenue producing on our Oculus collaboration continues to be profitable.
Ross Moat: In the first half of 2022, we recorded $49.2 million net revenue, and we continue to guide, to a range of $115 to $130 million for the totality of 2022.
Looking to the rest of the year. Our guidance is an estimated net revenue of $115 million to $113 million.
Ross Moat: On slide 10, I will dive into more detail on the drivers behind the recurrent pericarditis, revenue, starting with physician growth. As the awareness of Arclist for recurrent pericarditis continues to grow, so too does, the number of physicians who have prescribed Arclist.
Ross Moat: Since launch, we've seen a growth of around 100 additional prescribers per quarter, and, in Q2, we saw this jump to greater than 550 prescribers since launch.
Ross Moat: We believe that by closely supporting physicians through their prescribing experience and patients, throughout their journey on Arclist, we will trigger further prescribing when physicians identify their next appropriate patient.
Importantly, as Mark reiterated we are well capitalized and after the close of the Victrola map deal with Roche Genentech, our cash reserves are expected to fund as you said into at least 2025.
With that license agreement and our continued commercial performance in Arcalis connector is in a very strong financial position.
Ultimately we are determined to continue to help patients in need create massive value and aim to fulfill our goal of becoming a global generational company.
Ross Moat: Rydyn ni'n dechrau gweld y gweithredu hwnnw.
Ross Moat: Yn ystod unrhyw gwybodaeth, rydyn ni wedi cael 20% o'r gwasanaeth presbrydol cyfan, sydd wedi'i gwasanaethu i ddau neu mwy o gwasanaethau.
With that I want to thank you all for your time today and hand, it back to the operator for questions.
Ross Moat: Mae hyn yn brofiad gwych oherwydd bod gwasanaeth biologaidd yn dal yn newid ymlaen i llawer o cardiologwyr.
Ross Moat: Mae hefyd yn bwysig bod nhw'n gweld ar y rhan o'r penderfyniad, bod gwasanaethau'n cael gysylltiad gyda'r therapeutiaid.
Ross Moat: Yn yr adroddiad hon, rydyn ni'n dal i weld gwasanaethau cyhoeddus iawn, yn y rhan o'r 90%.
Thank you all speakers at this time I would like to remind everyone in order to ask a question Press Star then the number one on your telephone keypad, Jim we will pause for just a moment to compile the Q&A roster.
Ross Moat: Felly, gall gwasanaethwyr a therapeutiaid, fod yn hyderus iawn bod eu gwasanaethau'n canlyniad yn ymwneud â'r therapeutiaid.
Ross Moat: Yn amgylchedd, er bod hyn yn dal i ddigwydd, mae'r data ar gael yn dal i ddefnyddio gwasanaethau gwasanaethau cyhoeddus o am 12 mlynedd o'r therapeutiaid.
Your first question comes from the line of Geoff Meacham from Bank of America. Your line is open.
Ross Moat: Mae'r syniad hwn yn cael ei drifo gan rhan fwyaf o gwasanaethau sy'n cael eu gwrthwynebu am 12 mlynedd.
Ross Moat: Mae'r rhan fwyaf o gwasanaethau yn cael eu gwrthwynebu am 12 mlynedd yn ymwneud â gwasanaethau cyhoeddus, gwasanaethau cyhoeddus a therapeutiaid, ac ymhellach 45% o'r pobl sy'n cyhoeddu'r cyntaf o Q2 2021 sy'n ymwneud â therapeutiaid cyhoeddus drwy ddiwedd Q2 2022.
Ross Moat: Yn ogystal â hyn, mae Arclis wedi cael gwasanaeth cyhoeddus iawn o bobl mwy na 90%, ac rydyn ni'n ymwneud â'i gwrthwynebu'n ddiweddarach ac yn ddiweddarach ar y canlyniadau gwahanol y mae Arclis yn ei wneud i bobl sy'n diogelu o'r dysgwyr sy'n anhygoel.
Good morning. This is Jason on for Jeff. Thanks, So much for taking our questions and congratulations on the quarter.
Ross Moat: Mewn i slid 11, rydyn ni'n eisiau ymddangos pam rydyn ni'n cyffrous am y potensial ymlaen, yn ogystal â'r hyn rydyn ni wedi dysgu yn ymlaen.
Ross Moat: Yn gyntaf, rydyn ni wedi cael ymlaen gwych ar hyn o bryd, ac rydyn ni'n gwybod'r cyfle'n dda.
Ross Moat: Mae 14,000 o bobl, sy'n ymwneud â gwasanaethau cyhoeddus, sy'n golygu dwy neu mwy o gyhoeddus, yn unrhyw flynyddoedd.
Ross Moat: Ac, ar gyfer llyfr arbennig Arclis, gallai'n cael ei ddefnyddio efallai yn gyntaf yn y dysgwyr ar ôl un o'r cyhoeddus.
Ross Moat: Felly mae gennym gyfle mawr ymlaen, ac rydyn ni'n y dyddiau cyntaf o'r cyfle bywyd.
Ross Moat: Yn ddiweddarach, mae ein gwasanaethau gwahanol yn ymwneud â chyhoeddus Arclis a'i helpu i greu profiad gwasanaethau cyhoeddus a gwasanaethau cyhoeddus.
Hoping you can elaborate on maybe some of the nearer term.
Ross Moat: Yn y dyfodol, rydyn ni'n ei weld bod y ffysiynau yn dod yn ymwybodol ac yn gwybodol o gyhoeddus cyhoeddus a'r cyhoeddus Arclis, ac mae eu cyfathrebu neu'u cyfathrebu â'r cyhoeddus Arclis yn y blynyddoedd dysgwyr yn cynyddu'n sylweddol gyda 88% o'r cyhoeddwyr sydd wedi cysylltu gyda'r cyfathrebu yn dweud y bydd eu cyhoeddwyr yn tyfu yn y blynyddoedd ddod.
Ross Moat: Y tro, nid oes unrhyw nifer mawr o sefydliadau pericardiaid sy'n cynyddu'r cyhoedd ar dysgwyr pericardio.
Ross Moat: Mae hyn yn golygu, bod y pobl pericardiaid yn ymwneud â'r cyhoedd ac mae'r amgylchedd y mae pob ffysiynau yn ei weld yn ymwneud â'r cyhoedd.
With dynamic certainly sounds like youre hitting on a number of.
Key endpoints here, but maybe what are some of the nearer term levers.
It could potentially drive.
More of an acceleration and then as you think about expanding the sales force.
What are the opportunities here to move beyond kind of that initial bolus of 14.
<unk> 14000 patients to a broader base there. Thanks so much.
Thanks, Jay and thanks for the question Ross why don't you cover that yes, very happy to say Hi, Jason. This is Ross. Thanks, a lot for the question. So I think a lot of the.
Ross Moat: Efallai ynglyn â'r un sefydliad, gall y pobl gynhyrchu ar gyfer cyhoedd i ffysiynau gwahanol.
Ross Moat: Felly, oherwydd ein cyfathrebu ers ei ddechrau a'r effaith positif sy'n cael ei wneud ar gyfer ffysiynau, rydyn ni'n cynllunio ein cyfathrebu a'n gysylltiad trwy gynyddu ein tîm ffyrdd.
Ross Moat: Yn ymwneud ag ysgrifenni 12, rydw i eisiau gynllunio sut y byddwn yn cynyddu ein tîm ffyrdd.
Ross Moat: Rydyn ni'n credu'n ffyrdd, y bydd hyn yn ein gallu cynyddu penedraeth ffyrdd a'n ymwneud â cyfathrebu pobl ffyrdd.
Key metrics were looking at previously I'm moving forward and how we continue to execute really at the same as previously is kind of really focusing on the number of prescribers that we have the number of unique prescribers for the first time driving the number of those repeat prescribers of course, keeping a very keen eye on focus on compliance.
Adherence education on both the physician and the patient side.
Continuing to drive patient identification units that were flaring disease, and we have a lot of activities out in the field to try to.
Really Bruce the education, we're really pleased with the growth that we've had so far in Q in Q2, 22% growth. We feel like we have a nice a nice trajectory and we need to continue to focus and execute.
Got you and is there a sense that once prescribers kind of.
Canadian experience prescribing <unk>.
So that they can reach out to their colleagues and build that base or is that sort of.
Something more that the sales team.
Yes, Thanks, Greg.
Great point, and it's something that we're very much hoping is going to be the case and I think we're seeing that in.
In part already.
Pfizer, we have such a broad prescriber base and this is being taken up by so many.
Cardiologists and Theres not forget the biologics is still fairly new to cardiologists. So many of them have not had experienced prescribing before so the better the experience they get so once they do identify a patient and continue to do so and when they hear back from the patients about the clinical.
Factoring in results the patients are achieving.
The better and we hope that we are able to share that on our side as well as peer to peer doctor to Doctor education in Shanghai experiences, while I think that's vital all across the country.
Perfect. Thanks for the color.
Thank you Jason. Your next question comes from the line of <unk> Rama from J P. Morgan Your line is open.
Ross Moat: Fel argyfwng, rydyn ni'n cyhoeddi gyda'r tîm y byddwch chi'n ymwybodoli'n fawr a'r byddwch chi'n ymwybodoli'n fawr, o'r ystod y 30 o argyfwng argyfwng argyfwng argyfwng argyfwng sydd wedi'i ddarparu argyfwng argyfwng argyfwng argyfwng y byddwch chi'n ymwybodoli'n fawr.
Ross Moat: Mae'r tîm Lean yn ein galluogi i'n cymryd ymweld â 45% o'r patiention pericarditis argyfwng, ac rydyn ni'n ymdrechu'n fawr i gyfrannu cyfrannu ar gyfer y fransiwn sydd wedi'i hyrwyddo'n dda iawn yn y tîm llwyr gyntaf.
Hey, guys. Thanks, so much for taking the question congrats on all the progress sorry.
Ross Moat: Nawr rydyn ni'n gweithredu'r dysgu o ran ein lansiwn, ac yn amlwg i gynyddu ein cyfrannu trwy ddatblygu ein tîm ymdrechu trwy gael cyfrannu.
Sorry, if I missed it in the opening comments, but I know you noted that the proceeds from the <unk>.
Ross Moat: O ran lansiwn, rydyn ni wedi dysgu am bwysigrwydd ymddiriedol ar ein seilwyr argyfwng, yn ogystal â'r angen i gyfrannu ar gyfer tîm llwyr o lansiwyr yn ymdrechu ar gyfer unig ddoctorion unigol.
Ross Moat: Yn ystod y chyfnod yma, rydyn ni'n ymdrechu i ddatblygu o gwmpas 30 o gyfrannwyr, i ymdrechu â chyfrannwyr o gwmpas 50 o gyfrannwyr sy'n gallu cyfrannu â 6,000 o gyfrannwyr iechyd iechyd ac o gwmpas 70% o boblogaeth pericarditis argyfwng.
Ross Moat: Yn ogystal â hyn, rydyn ni hefyd yn adeiladu tîm llwyr o gyfrannwyr ymdrechu ymdrechu, fel ymdrech cyffredin i ddarganfod rhai o'r doctorion iechyd llwyr.
Transaction youre going to be looking for synergistic opportunity.
<unk> space. So does that include maybe external business development or is it kind of more focused on Maverick, which you noted in the PR and what does this mean around the strategy around PPL four O four thanks, so much.
Thanks, Bob.
As always seasonality so definitely.
Still looking very much a BD BD continues to be a very strong obviously you've seen from this deal in particular, but certainly this non diluted capital will definitely as well as what Russ described the Mark described is definitely go to investing in our existing franchise with <unk>, but on top of that we will be looking to potentially augment our portfolio with.
Other immune.
Immune modulating therapies, hopefully within the cardiovascular space. So it's certainly not capital could go towards that but besides that we continue to be very encouraged with our own portfolio. So you are right. <unk>. Four continues we are enrolling in that phase II study with described in rheumatoid arthritis. So that we continue to progress that and we're excited about that obviously again.
This is a molecule an asset that we pretty much almost fully own the economics around so that's exciting and again with mobile Internet and I think the idea is that potentially there as well and we're looking at potential indications and the more rare cardiovascular front again, leveraging that expertise and that infrastructure that we have.
But on top of that as you said BD is very much a focus for us. So we're excited and the additional runway. We've got is fantastic. So as I said at least into 2025. So it's.
A good time to be a connection.
Thanks, so much for taking my questions.
Okay.
Thank you Edwin.
Your next question comes from the line of Paul Choi from Goldman Sachs. Your line is open.
Hi, This is roderic, Paul Paul Thanks for taking our questions and so we have capo and maybe the first one is for the upfront payments from Genentech, where would that be one time payment or.
Amortized over a certain period.
Yes, so what we've said is $100 million.
Upfront and near term essentially what that is is $80 million.
Upfront immediately and then the $20 million.
There's some supply obligations that we expect in the relatively near term to release $100 million of near upfront and maybe Mark can cover how we plan to monetize it.
Yes.
Thank you for the question I think we're still in the early stages here and working.
With our auditors to determine the details in the proper way to recognize the revenue. So so more to come on that front.
Down the line.
Thanks, and maybe just another question.
Can you just.
What is the relative rate, possibly that.
Can be difficult.
The royalty rate.
Yes so.
Royalties on annual net sales.
For the Genentech agreement are ranged from a low double digits to the mid teens.
Got it and Thats fulfilling our upstream financial obligations zoro and less got it.
Yes.
And maybe just the last one on the pipeline so.
You mentioned that the BD properly.
One of the areas you are looking for looking to and maybe just on your current pipeline.
What is your priority for now.
Yes.
For the question.
Looking at it.
We're incredibly happy with our pipeline and lots.
Lots of investment opportunities.
We've historically said, we have an incredibly high bar for bringing new programs programs and it's always a tradeoff between.
Investment in your own portfolio with all of the exciting opportunities we have versus external that being said we're <unk>.
Really active and we continue to look at.
Opportunities and if we think that there is.
A larger benefit for bringing something in that investing in the pipeline well, we will do so but that remains an incredibly high bar as we.
I think we have many things to invest in that are incredibly valuable to patients.
Thanks for that.
Thank you all speakers there are no further questions at this time I'll turn the call back over to Sanjay Patel.
Ross Moat: Bydd y cyfrannwyr hyfryd hwn yn creu cyfrannwyr mwyaf gyda'n doctorion iechyd llwyr, ond hefyd yn cynyddu ein gallu i ddarganfod cymaint o cardiologwyr sy'n ymdrechu â chyfrannwyr iechyd pericarditis argyfwng.
Thanks, operator, so again, thanks, everybody for the questions and joining the call today, hopefully you get a sense of the excitement. We've got here. We're very excited by this deal obviously the continued execution around <unk> and also the progressing of the pipeline. So we look forward to providing additional updates throughout rest of the year have a great day everybody. Thank you.
Ross Moat: Mae'r rhan fwyaf yw ein bod ni'n ddiddorol iawn gyda'n ramp cyntaf o ddechrau.
Ross Moat: Rydyn ni'n cynnwys ffrantisiaeth cyfrannwyr a rydyn ni nawr yn ymwneud â'r cyfle, i ddarganfod y bywydau o ddarganfod cyfrannwyr iechyd pericarditis argyfwng yn fwy cyflym.
Ross Moat: Yn amgylchedd, rydyn ni'n credu ein bod ni ar y dechrau o ddarganfod cyfyngedig, o ffrantisiaeth cyfrannwyr sy'n cynydduol a phroffesiynol.
Ross Moat: Ers ddechrau, rydyn ni wedi gweld cynyddu sylweddol, cyffredinol, gweithredu cyffredinol, ym mhwrdd â'r mhwrdd.
Ross Moat: Mae'r ymdrechwyr, y pwyllgorau a'r patientau yn ymdrechu i ymdrechu'n eithaf positif, ym mhwrdd â'r ymdrechwyr sy'n ymdrechu i ymdrechu'n eithaf positif, ac mae mwy a mwy o bwysigwyr yn cael eu diagnogi'n dda a'u darparu gyda ddarganfod cyfyngedig sy'n ei ddysgu i ddarlunio'r dyrfa sylweddol o'r dyfyddiad.
Sanj Patel: We're focused on continuing to execute across our current portfolio, as well as developing, the portfolio in line with our existing cardiovascular expertise and infrastructure.
Ross Moat: Yn y chweithiau cyntaf 2022, rydyn ni wedi cydnabod $49.2 miliwn o gyllideb gynllunol, ac rydyn ni'n ymdrechu i $115 miliwn i $130 miliwn ar gyfer y blynyddoedd.
Sanj Patel: On the commercial side, as Ross said, we're revenue-producing, and our Arcalyst collaboration, continues to be profitable.
Ross Moat: Rydyn ni'n ddiddorol iawn i ddefnyddio'r stæp i ddatblygu ein tîm ym mhrydol, yn Q4 ac i ddod yn well, yn fwy cyflym, yn fwy gryf.
Sanj Patel: Looking to the rest of the year, our guidance is an estimated net revenue of $115 to $130, million. Importantly, as Mark reiterated, we are well-capitalized, and at the close of the Vix-Relamab deal with, Roche Genentech, our cash reserves are expected to fund, as he said, into at least 2025.
Mark Ragosa: Rydw i'n cyflwyno i Mark i gyflwyno ein canlyniadau ariannol.
Sanj Patel: With that license agreement and our continued commercial performance in Arcalyst, Connexa, is in a very strong financial position.
Mark Ragosa: Mark.
Sanj Patel: Ultimately, we are determined to continue to help patients in need, create massive value, and aim to fulfill our goal of becoming a global generational company.
Mark Ragosa: Diolch, Ross.
Sanj Patel: With that, I want to thank you all for your time today, and I'll hand it back to the operator for questions.
Operator: At this time, I would like to remind everyone, in order to ask a question, press star, then, the number one on your telephone keypad, and we will pause for just a moment to compile the Q&A roster.
Mark Ragosa: Helo, bawb.
Operator: Thank you all speakers.
Mark Ragosa: Gall ein canlyniadau ariannol ym mhwyrdd ddau, 2022, cael eu cyflwyno yn y cyflwyno cyhoeddus rydyn ni'n ei ddatblygu yn y diwrnod diwethaf.
Mark Ragosa: Mae yna rhai eitemau y byddwn i eisiau ei adros i chi yma y diwrnod hwn, a digwyddiadau gorau'n cymryd rhywun fy mhwyrdd a cyl, yn 46.3 miliwn a rhyw 20 miliwn, o ran gwirionedd argyfwng aörlles argyfwng Arclis a'r holl oddi i gangson y Graffiti a'r trygfa Mhwyrdd.
Mark Ragosa: Fourth, our net cash burn improved in the second quarter of this year with the receipt, of a $22 million upfront payment from our collaboration with Wodong Medicine.
Operator: Your first question comes from the line of Jeff Meacham from Bank of America.
Mark Ragosa: And lastly, we remain well-capitalized with a cash balance at the end of the second quarter, of approximately $138 million, and we expect these reserves, combined with the proceeds from the VIXA Global License Agreement announced this morning, as well as continued Arcalyst, Commercial Execution to fund our current operating plan into at least 2025.
Operator: Your line is open.
Mark Ragosa: And with that, I'll turn the call back to Sanj for closing remarks.
Jason: Good morning.
Sanj Patel: Thanks, Mark.
Jason: This is Jason.
Sanj Patel: In addition to our successful commercial launch in recurrent pericarditis, we're also building, a foundation as an emerging leader in immune modulating therapies.
Jason: Jeff, thank you so much for taking our questions, and congratulations on the quarter.
Operator: This concludes today's conference call. You may now disconnect.
This concludes today's conference call you may now disconnect disconnect.
Jason: I was hoping you could elaborate on maybe some of the nearer-term Arcalyst dynamics.
Jason: It certainly sounds like you're hitting on a number of key endpoints here, but maybe, what are some of the nearer-term levers that you think could potentially drive more of an acceleration?
Jason: And then, as you think about expanding this sales force, what are the opportunities here, to move beyond that initial bolus of 14,000 patients to a broader base there?
Jason: Thanks so much.
Sanj Patel: Thanks, Jason.
Sanj Patel: Thanks for the question.
Okay.
Sanj Patel: Ross, why don't you cover that?
Yes.
Ross Moat: Yeah, I'm very happy to.
[music].
Ross Moat: Hi, Jason.
Ross Moat: This is Ross.
Ross Moat: Thanks a lot for the question.
Ross Moat: I think a lot of the key metrics that we're looking at previously and moving forward and, how we continue to execute really at the same as previously is really focusing on the number of prescribers that we have, the number of unique prescribers for the first time, driving the number of those repeat prescribers, of course, keeping a very keen eye and focus on compliance, adherence, education on both the physician and the patient side, and really continuing to drive patient identification.
Ross Moat: This is a rare, flaring disease, and we have a lot of activities out in the field to try, to really boost the education.
Ross Moat: We're really pleased with the growth that we've had so far.
Ross Moat: Is there a sense that once prescribers gain experience prescribing Arcalis, that they, can reach out to their colleagues and build that base, or is that something more that the sales team can do?
Ross Moat: Yeah, no thanks, that's a great point, it's something that we're very much hoping is going, to be the case, and I think we're seeing that in part already, the fact that we have such a broad prescribing base, and this is being taken up by so many cardiologists, and let's not forget that biologics are still fairly new to cardiologists, so many of them have not had experience prescribing before, so the better the experience they get once they do identify a patient, and continue to do so, and when they hear back from the patient about the clinical effect and results the patients are achieving, the better, and we hope that we are able to share that on our side, as well as peer-to-peer, doctor-to-doctor education, and share of that experience as well, I think that's vital all across the country.
Ross Moat: Perfect, thanks for the call.
Ross Moat: Thank you Jason.
Operator: Your next question comes from the line of Anupam Rama from J.P. Morgan, your line is open.
Anupam Rama: Hey guys, thanks so much for taking the question, congrats on all the progress, I'm sorry if, I missed this in the opening comments, but I know you noted that the proceeds from the VIXA transaction, you're going to be looking for synergistic opportunities in the CV space, so does that include maybe external business development, or is it kind of more focused on MAVRI, which you noted in the PR, and what does this mean around the strategy around
Anupam Rama: KPL-404?
Anupam Rama: Thanks so much.
Thanks.
Sanj Patel: Thanks Anupam, as always, you've nailed it.
Yes.
Sanj Patel: So definitely still looking very much at BD, BD continues to be a very strong, obviously, you've seen from this deal in particular, but certainly this non-diluted capital will definitely, as well as what Ross described and Mark described, definitely go to investing in our existing franchise with Arklis, but on top of that, we will be looking to potentially augment our portfolio with other immune modulating therapies, hopefully, within the cardiovascular space, so certainly that capital could go towards that, but beside that, we continue to be very encouraged with our own portfolio, so you're right, KPL-404 continues, we are enrolling in that phase two study, we've described rheumatoid arthritis, so that we continue to progress that, and we're excited about that, obviously again, this is a molecule, an asset that we pretty much almost fully own the economics around, so that's exciting, and again, with Mavalin on that, I think the ideas are potentially there as well, we're looking at potential indications in the more rare cardiovascular front, again, leveraging that expertise and that infrastructure that we have, but on top of that, as you said, BD is very much a focus for us, so we're excited, and the additional run that we've got is fantastic, so as I said, at least into 2025, so it's a good time to be a connector.
Anupam Rama: Thanks so much for taking our questions.
Yes.
Operator: Thank you, Anavam.
Operator: Your next question comes from the line of Paul Choi from Goldman Sachs, your line is open.
Roderick: Hi, this is Roderick for Paol.
[music].
Roderick: Thanks for taking our questions.
Roderick: And so we have a couple. And maybe the first one is for the upfront payment from Genentech.
Roderick: Will that be a one, time payment or amortized over a certain period?
Sanj Patel: Yeah, so what we've said is $100 million in upfront and near term. Essentially what that, is, is $80 million that will come up front immediately. And then there are $20 million in some supply obligations that we expect in the relatively near term too. So really it's $100 million of near and up front.
Okay.
Sanj Patel: And maybe Mark can cover how we plan to amortize it.
Mark Ragosa: Yeah, and thank you for the question.
Mark Ragosa: I think we're still in the early stages here and working, with our auditors here to determine the details in the proper way to recognize the revenue.
Mark Ragosa: So more to come on that front down the line.
[music].
Roderick: Okay, thanks.
Roderick: And maybe just another question.
Roderick: What is the relative rate possibly that can, be disclosed?
Okay.
Roderick: The royalty rate?
Sanj Patel: Yeah, so the royalties on annual net sales for the Genentech agreement, range from low double digits to the mid-teens.
Sanj Patel: Got it.
Sanj Patel: And that's before fulfilling our upstream financial obligations to our licensing.
Roderick: And maybe just the last one on the pipeline.
Roderick: So you mentioned that BD probably is one of, the areas you're looking into.
Roderick: And maybe just on your current pipeline, what is your priority for now?
Sanj Patel: Yeah, no, thanks for the question.
Sanj Patel: We're incredibly happy with our pipeline and have lots of investment, opportunities.
Sanj Patel: And that's why we've historically said we have an incredibly high bar for bringing new programs in.
Sanj Patel: It's always a tradeoff between investment in your own portfolio with all of the exciting opportunities we have versus external.
Sanj Patel: That being said, we're highly active and we continue to look at opportunities.
Sanj Patel: And, if we think that there is a larger benefit for bringing something in than investing in the pipeline, well, we'll do so.
Sanj Patel: But that remains an incredibly high bar as we think we have many things to invest in that are incredibly valuable to patients.
Roderick: Thanks for that.
Operator: Thank you all speakers.
Operator: There are no further questions at this time.
Operator: I turn the call back over to Sanj Patel.
Sanj Patel: Thanks, operator.
Sanj Patel: So again, thanks everybody for the questions and joining the call today.
Sanj Patel: Hopefully, you get a sense of the real excitement we've got here.
Sanj Patel: We're very excited about this, deal, obviously the continued execution around ArcLis and also the progressing of the pipeline.
Sanj Patel: So we look forward to providing additional updates throughout the rest of the year.
Sanj Patel: Have, a great day, everybody.
Operator: Thank you.